Cancer-cell-associated biomarker or receptor

A cancer-cell-associated biomarker or receptor refers to a broad category of biological molecules—such as proteins, nucleic acids, or lipids—that are found in blood, other body fluids, or tissues and signify an abnormal process, condition, or disease like cancer (National Cancer Institute, 2023). These entities are often overexpressed or mutated in malignant cells, playing pivotal roles in cell proliferation, survival, and immune evasion (Goossens et al., 2015). In clinical oncology, they serve as essential targets for precision medicine, allowing for the development of targeted therapies such as small molecule inhibitors and monoclonal antibodies (Chandra et al., 2023). Because this term describes a diverse group of molecules rather than a single protein or gene, it is used as a conceptual framework for identifying therapeutic vulnerabilities in various malignancies (Henry & Hayes, 2012). Common examples include the Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer and the Epidermal Growth Factor Receptor (EGFR) in lung cancer. These markers are critical for patient stratification, diagnostic accuracy, and monitoring therapeutic efficacy. However, the inherent heterogeneity of tumors and the development of bypass signaling pathways present significant challenges to drugs targeting these biomarkers.

Other names

Tumor-associated antigenCancer biomarkerTumor markerOncoproteinTumor-specific antigen

The mechanism of action varies significantly depending on the specific biomarker or receptor; common strategies include competitive inhibition of kinase domains, blockade of ligand-binding sites on extracellular receptors, and induction of antibody-dependent cellular cytotoxicity (ADCC) (National Cancer Institute, 2023; Goossens et al., 2015).